Inergetics' New CEO Determined To Breathe New Life Into Clinical Health and Sports Supplements Firm

Wed Oct 17, 2012 8:17am EDT

* Reuters is not responsible for the content in this press release.

This past summer, Michael James was appointed to the CEO of Inergetics, Inc.(OTCBB: NRTI) - a leading developer of nutritional supplements for the Clinical Health and Sports Supplement markets.

With a new team at the helm, is this penny stock firm finally ready to start delivering on its promise as a sports and health nutrition company?

Rising to the top of the world of nutritional supplements for the Clinical Health and Sports Supplement markets has proven to be tricky for a number of companies.

After a couple of years trying to crack the code for success, the new leadership group at Inergetics- the developer of SurgexR ; a sports nutrition formula designed  to meet the nutritional needs of professional, Olympic and amateur elite athletes that experience post-workout symptoms such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function- finaly feels they have firm footing and a number of upcoming catalysts (including some merger and acquisition activity) that may help.

In addition, very recently, Dr. David L.Blecker MD., a leader in the nephrology space joinedthe firm's Advisory Board after seeing promising nutritional benefits from prescribing the drink formula to a limited number of dialysis patients. Blecker, who owns and operates a number of Dialysis units and is as partner in Regional Nephrology Associates is heading up a pre-marketing clinical study which may open up an entirely new and potentially lucrative market, for NRTI's line of Resurgex(TM) products-- which are designed to provide comprehensive nutritional support for actively treated cancer patients as well as those in post-treatment care and elderly members of the assisted living community.

A purely speculative penny stock play, the company finally feels they have positioned themselves as a "cleaned up candidate" which may finally start to realize some of the promise that James saw when he first invested some of his own money in the firm a number of years ago.

"It looks very positive, I'm the most excited I've been about the firm since I've been there," says James in an exclusive video interview. "I went in as the cheif finaincial officer and we cleaned up a lot of the debt. We converted a lot of the debt into equity and now we have a marketing team who has done it before at two other companies- proven successfully... We've finally got the team in place to move together a build a business."

The complete video interview with James about NRTI is available at:

http://www.biomedreports.com/20121017109356/qaa-the-bounce-back-of-inergetics.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

####

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com

Disclosure: Long NRTI





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: BioMedReports via Thomson Reuters ONE

HUG#1649959
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.